Cost of cataract surgery after implantation of three intraocular lenses

Catherine Boureau¹
Antoine Lafuma²
Viviane Jeanbat²
Andrew F Smith³
Gilles Berdeaux⁴

¹Clinique Geoffroy St Hilaire, Paris, France; ²Cemka-Eval, Bourg la Reine, France; ³Alcon Laboratories Ltd, Hemel Hempstead, UK and Nuffield Laboratory of Ophthalmology, University of Oxford, UK; ⁴Alcon France, Rueil Malmaison, France; Conservatoire National des Arts et Métiers, Paris, France

The results of this study were first presented at the 9th annual congress of ISPOR, 29−31th October 2006, Copenhagen, Denmark

Background: Posterior capsule opacification is one of the most frequent adverse events following cataract surgery. This manuscript reports the lifetime cost of complications linked to posterior capsule opacification using three types of intraocular lens with square edges.

Methods: Costs were estimated from a retrospective study of patients who underwent cataract surgery and data from the literature. The lenses studied were hydrophobic acrylic (SA60AT and AR40E) and hydrophilic acrylic (XL-Stabi) lenses with square edges. The frequency of Nd-Yag laser capsulotomies after 4 years’ survival was estimated by two methods: the first involved linear adjustment of the rate at 5 and 6 years follow-up and then application of a constant rate after 6 years; the second involved linear adjustment after 5 years follow-up. The economic perspective was that of the French Sickness Fund.

Results: After 3 years’ follow-up the percentage of patients who had not undergone laser Nd-Yag capsulotomy was 86.9% with SA60AT, 76.6% with AR40E and 54.6% with XL-Stabi lenses (p<0.001). The total cost of capsulotomy and management of complications per patient lifetime was estimated to be €90.5 for SA60AT, €189.5 for AR40E and €288.0 for XL-Stabi lenses by the first extrapolation method. With the second method of extrapolation the costs were €94.8, €200.0 and €300.2, respectively.

Interpretation: Lower costs for cataract surgery and management of related complications were observed with the two hydrophobic acrylic lenses; the lowest costs were observed with SA60AT lenses as they were associated with fewer Nd-Yag laser capsulotomies.

Keywords: cataract surgery, Nd-Yag laser, capsulotomy, adverse event, cost, budget impact

Introduction

The most frequent postsurgical complication of cataract surgery is posterior capsule opacification (PCO),¹ which affects at least 20% of patients 3 years after surgery and around 38% 9 years after.² When PCO becomes severe and affects the visual acuity of the patient, treatment by laser neodymium-Yag (Nd-Yag) is carried out.³

Secondary effects of laser-Yag capsulotomies are generally rare and transient, except for the formation of Elschnig pearls and elevation of intraocular pressure (IOP). The increase in IOP affects 4% to 7% of patients, particularly those with ocular comorbidities such as glaucoma, strong myopia or aphakia.⁴⁻⁻ Kato et al⁵ observed an increased rate of formation of Elschnig pearls after capsulotomy in 47.6% of the eyes, 12 months after capsulotomy. Formation of these pearls required a second operation in approximately 1/3 of eyes affected. According to Kurosaka,⁶ 69.2% of the eyes developed Elschnig pearls during the 32.1 months post laser Nd-Yag follow-up.

The other secondary effects of cataract surgery generally affect less than 3% of patients. Rollin et al⁷ observed several cases of transient ocular hypertension and uveitis, and a single case of cystoid macular edema (CMO) after Nd-Yag laser. Boschi et al⁸ reported an incidence of CMO of 3.1%, an elevation of IOP in 11.9% and alteration of the lens in 27%.
Retinal damage after capsulotomy is a rare event. According to Javitt et al., the risk of retinal detachment was 3.9 times higher (CI 95%: 2.89–5.25) in patients who had capsulotomy. The risk of retinal tearing was 2.24 times higher in patients who had capsulotomy.

In a recent study, Billotte and Berdeaux developed a Markov model to evaluate the frequency of complications following capsulotomy using data from the literature. If the intraocular lens (IOL) is replaced to reduce the frequency of laser Nd-Yag capsulotomies from 10% to 2.5%, 1201 detachments of the retina, 1201 CMO, 1342 cases of glaucoma and 5882 increases in IOP per year would be avoided per 400,000 subjects undergoing cataract surgery per year during the 3 years post surgery.

The costs linked to cataract surgery include insertion of the IOL but also costs linked to management of complications, including the cost of capsulotomies and related secondary effects. The frequency of capsulotomy depends mainly on the type of lens inserted. This analysis compared the costs over the lifetime of the patient after cataract surgery using three types of lens with square edges.

Materials
This economic analysis was performed from the perspective of the French Sickness Fund. It was based on the results of a retrospective analysis of patients picked up at random implanted with square edge IOLs. These clinical results were extrapolated to the entire life of the cohorts to allow calculation of the lifetime costs for the population.

Study plan
This retrospective, multicentric study was carried out in France by 10 ophthalmology centers. IOLs studied all had square edges: AcrySof® SA60AT (Alcon), AR40E (Advanced Medical Optics) and XL-Stabi (Zeiss-Ioltech). SA60AT and AR40E are hydrophobic acrylic lenses and XL-Stabi is a hydrophilic acrylic lens. The results of the multicentric retrospective study have been described in a previous publication. 767 eyes treated with SA60AT (n = 250), AR40E (n = 254), or XL-Stabi (n = 263) were analyzed. After 3 years’ follow-up the proportions of patients who had not received Nd-Yag laser treatment were 86.9% with SA60AT, 76.6% with AR40E, and 54.6% with XL-Stabi (p < 0.001). Cox’s model adjusted for center effects and the presence of diabetes estimated risk ratios of 2.8 for AR40E (p < 0.0005) and 5.1 for XL-Stabi (p < 0.0001), compared to the reference lens SA60AT.

Evaluation of the rate of laser Nd-Yag capsulotomies and data extrapolation
The survival curves resulting from the retrospective study provided a rate of capsulotomy during 4 years of follow-up. After this 4-year follow-up period, two extrapolation methods were used to evaluate the frequency of Yag:

1. Linear extrapolation of the survival curves from 5 years to 26 years of follow-up (that is, until the age of 100 years; patients had a mean age of 74 years at the time of surgical intervention in the retrospective study). The rate of Yag was calculated according to the following method:
   \[ \text{Rate of Yag at } y \text{ years of follow-up} = \frac{\text{cumulative rate of Yag at } y \text{ years} - \text{cumulative rate of Yag at } (y-1) \text{ years}}{y} \]
   It was necessary to divide the rate of Yag by two to fit with long term cohort follow-up curves.

2. Extrapolation of the survival curves from 5 to 6 years of follow-up, with a constant rate of laser Nd-Yag from then on. Indeed, Billotte et al. demonstrated that beyond 6 years of follow-up, the cumulative rate of capsulotomies remains constant. The rate of Yag was calculated according to the following method:
   \[ \text{Rate of Yag at } y \text{ years of follow-up} = \frac{\text{cumulative rate of Yag at } y \text{ years} - \text{cumulative rate of Yag at } (y-1) \text{ years}}{2} \]

Finally, a rate of capsulotomy taking into account survival was calculated to obtain the rate of Yag in the population included at each instant t. This rate was then used in the estimation of costs.

Survival rates were obtained from the INSEE data of January 1st 2005 (http://www.insee.fr).

Consumption of care
Only health care consumption associated with Nd-Yag laser and its complications was estimated, since the cost of cataract surgery itself was similar for the three lenses. It was estimated by the centers that participated in the retrospective European study, for each type of complication identified in a review of the literature.

Direct unit costs
Cost were expressed in Euro, 2006 (€1 = US$1.35). Two discount rates were used: 0% and 5%.
The costs of treatment and their level of reimbursement were obtained directly from the Dictionnaire Vidal 2006. The costs were reimbursed at 65% by the Sickness Fund.

The costs of medical examination and consultations were obtained from the Classification Commune des Actes Médicaux (CCAM) and the Nomenclature Générale des Actes Professionnels (NGAP) 2005 (http://www.insee.fr). These were reimbursed at 70% by the Sickness Fund, with an inclusive fee of €1 for the patient for consultations.

The costs of hospitalization were obtained the “Programme Médicalisé des Systèmes d’Information” (PMSI) (http://www.insee.fr). The most relevant Diagnosis Related Group (DRG) was chosen using the diagnostic classification of the International Classification of Diseases (ICD).

**Indirect unit costs**

The low vision and blindness incidence rates following glaucoma or high intraocular hypertension were estimated from the literature. According to Coffey et al the prevalence of blindness was 7.3% among glaucoma patients and 14.6% for low vision. Chen et al estimated at 15 years that cumulative incidence rate for low vision was 14.6% and 6.4% for blindness. Hattenhauser et al found very similar estimates: 27% (low vision) and 9% (blindness), at 20 years. We applied an average yearly incidence rate which was hypothesized to stay constant over the time horizon of our model.

Indirect costs are those costs associated with the development of blindness. They take into account all the socialized costs (converting the accommodation, moving home, help with house work, cooking, etc), the loss of revenue due to visual handicap, the hourly cost of helpers caring for the blind and the social financial help for the handicap. These costs were estimated at €7,242/person/year and €16,679/person/year, for low vision and blindness, respectively, in France.

**Evaluation of costs per complication**

The costs for transient complications were estimated using the following formula:

\[
\text{Cost/year of follow-up for a given complication} = (\text{final rate of Yag}) \times (\% \text{ complication}) \times (\text{cost of complication})
\]

For permanent complications (glaucoma and persistent elevation of IOP), we multiplied the annual cost per life expectancy taking into account patient gender:

\[
\text{Cost/year of life of follow-up for a given complication} = (\text{rate of Yag}) \times (\% \text{ complication}) \times (\text{annual cost of complication}) \times (\text{life expectancy in years})
\]

A model of budget impact for the Sickness Fund was also designed to calculate costs using the hypothesis that all lens implantations were carried out with one of the three lenses.

**Results**

**Rate of laser Nd-Yag**

Figure 1 shows the calculated rate of patients not undergoing laser Nd-Yag capsulotomy for each of the three IOL using the two described extrapolation methods. The lowest rate was observed with the hydrophilic acrylic lens, XL-Stabi, with 54.6% of patients not affected at 3 years of follow-up.

**Rate of post-laser Nd-Yag complications and health care consumption**

Only the most frequent or most serious complications were considered in this analysis:

- Transient increase in IOP: according to published studies, the frequency of IOP increase greater than 10 mmHg after capsulotomy ranges from 4.1% to 6.8%. For the evaluation of costs, an average rate of 5% was used. In 1% of cases this increase is persistent.
- The appearance of glaucoma: the incidence varies from 0.2% to 6.7% according to different studies, with a median of 1.34%. The rate considered in this study was 1.34%. A rate of 7.3% was used to estimate the indirect costs linked to the possibility of becoming blind following glaucoma.
- CM0: the incidence of CM0 varies from 0.55% to 4.9% according to different studies, with a median of 1.2%. The rate considered in this study was 1.2%.
- Detachment of the retina: the incidence varies from 0.08% to 4.16% according to different studies with a median of 1.2%. The rate considered here was 1.2%.
- Decrease in visual acuity: the incidence varies from 1.4% to 7%, with a median of 4%. The rate considered in this study was 4%.
- Formation of Elschnig pearls: approximately 47.6% of patients are affected. A second capsulotomy is necessary to remove these pearls in 18% to 33% of cases, with a mean of 25% of cases.

Table 1 shows the health care consumption for each of these complications. These data were obtained by questioning the centers that participated in the retrospective European study.

**Total cost of complications**

The cost of cataract surgery was the same for all three lenses and was not taken into account in the analysis. In France,
Figure 1  Annual rates of patients not undergoing Nd-Yag per lens according to two levels of extrapolation.
the IOL cost is included in the DRG price corresponding to the intervention.

A cost per episode was estimated for the transient complications (Table 2).

For the persistent complications, an annual cost was calculated and applied for each year of survival of the patient.

Cost of complications according to type of IOL
According to the method of extrapolation used, the highest costs were observed for the hydrophilic acrylic lens, XL-Stabi, with a cost per patient of €318.74 to €330.71 (Table 3). Out of the two hydrophobic acrylic lenses, SA60AT was associated with the lowest costs of €99.83 to €104.17 depending on the extrapolation method compared to €208.15 to €218.38 for AR40E. A 5% discount rate did not modify the results dramatically.

Irrespective of the extrapolation method or type of lens, the cost of laser Nd-Yag represents approximately 24% of the total cost of cataract surgery complications. The indirect costs linked to glaucoma and persistent elevation of IOP leading to blindness are also an important part of the total cost as they represent approximately 1/3 of the cost overall.

Budget impact model according to type of lens
According to the PMSI data for 2005, 529,987 interventions for cataracts were carried out. The three types of lens studied

---

**Table 1 Medical consumption according to the type of side effects**

<table>
<thead>
<tr>
<th>Post-laser Nd-Yag side effects</th>
<th>% of patients affected</th>
<th>Consultations (n)</th>
<th>Treatments</th>
<th>Examinations</th>
<th>Hospitalizations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transient increase in IOP</td>
<td>5.00%</td>
<td>2</td>
<td>Timolol + xalatan, azopt (50%)</td>
<td>Visual field + gonoscopy (50%)</td>
<td>–</td>
</tr>
<tr>
<td>Glaucoma and persistent elevation of IOP</td>
<td>Glaucoma: 1.34% IOP: 1.00%</td>
<td>2.5</td>
<td>Timolol + xalatan or azopt (50%) + betoptic</td>
<td>Visual field + gonoscopy (50%)</td>
<td>Trabeculotomy in 24.2% of cases. CCAM</td>
</tr>
<tr>
<td>Cystoid macular edema</td>
<td>1.20%</td>
<td>3.5</td>
<td>Indocilmyre + timolol or azopt (50%)</td>
<td>Angiography (50%)</td>
<td>–</td>
</tr>
<tr>
<td>Detachment of the retina</td>
<td>1.20%</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>02C02V/02C02W detachment of the retina</td>
</tr>
<tr>
<td>Decrease in visual acuity</td>
<td>4.00%</td>
<td>3</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Elschnig pearls</td>
<td>47.60%</td>
<td>1</td>
<td>Indocilmyre + laser Nd-Yag in 25% of cases</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Table 2 Unit costs of laser Nd-Yag and its complications**

<table>
<thead>
<tr>
<th>Post-laser Nd-Yag complications</th>
<th>Cost in the 1st year (€)</th>
<th>Annual cost in the following years (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laser Nd-Yag</td>
<td>98.16</td>
<td>0</td>
</tr>
<tr>
<td>Transient increase in intraocular pressure</td>
<td>62.16</td>
<td>0</td>
</tr>
<tr>
<td>Persistent increase in intraocular pressure</td>
<td>277.30</td>
<td>277.30</td>
</tr>
<tr>
<td>Glaucoma (direct costs)</td>
<td>277.30</td>
<td>277.30</td>
</tr>
<tr>
<td>Cost of low vision</td>
<td>7,242</td>
<td>7,242</td>
</tr>
<tr>
<td>Cost of blindness</td>
<td>15,679</td>
<td>15,679</td>
</tr>
<tr>
<td>Macular edema</td>
<td>108.13</td>
<td>0</td>
</tr>
<tr>
<td>Detachment of the retina</td>
<td>3023.54</td>
<td>0</td>
</tr>
<tr>
<td>Decrease in visual acuity</td>
<td>96.32</td>
<td>0</td>
</tr>
<tr>
<td>Elschnig pearls</td>
<td>36.31</td>
<td>0</td>
</tr>
</tbody>
</table>

**Abbreviation:** Nd-Yag, neodymium-Yag.
here represented 64% of the market: 38% for SA60AT, 12% for AR40E and 14% for XL-Stabi. This therefore represents:

- 204,045 interventions with SA60AT
- 63,598 interventions with AR40E
- 74,198 interventions with XL-Stabi, or a total of 341,842 interventions.

Assuming that all of these 341,842 interventions were carried out with the same IOL, we can estimate that the hydrophilic IOL, XL-Stabi, generated an additional cost of €67.5 to €70.2 million (depending on the extrapolation method used) as compared to SA60AT (Table 4). Considering the AR40E hydrophobic lens, the induced incremental cost as compared to SA60AT is lower than that of XL-Stabi. Nevertheless, this

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Lifetime cost of post-capsulotomy complications per patient and according to type of lens, according to the method of extrapolation used (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Linear extrapolation of the rate of Yag at 5 and 6 years follow-up, and then a constant rate</strong></td>
<td></td>
</tr>
<tr>
<td>Laser Nd-Yag</td>
<td>SA60AT</td>
</tr>
<tr>
<td>Laser Nd-Yag</td>
<td>21.29</td>
</tr>
<tr>
<td>Transient increase in IOP</td>
<td>0.67</td>
</tr>
<tr>
<td>Persistent increase in IOP</td>
<td>6.35</td>
</tr>
<tr>
<td>Persistent increase in IOP leading to blindness (indirect costs)</td>
<td>18.09</td>
</tr>
<tr>
<td>Glaucoma (direct costs)</td>
<td>8.51</td>
</tr>
<tr>
<td>Glaucoma leading to blindness (indirect costs)</td>
<td>24.24</td>
</tr>
<tr>
<td>Macular edema</td>
<td>0.28</td>
</tr>
<tr>
<td>Detachment of the retina</td>
<td>7.83</td>
</tr>
<tr>
<td>Decrease in visual acuity</td>
<td>8.82</td>
</tr>
<tr>
<td>Elschnig pearls</td>
<td>3.75</td>
</tr>
<tr>
<td><strong>Direct costs</strong></td>
<td><strong>57.49</strong></td>
</tr>
<tr>
<td><strong>Indirect costs</strong></td>
<td><strong>42.34</strong></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>99.83</strong></td>
</tr>
<tr>
<td><strong>Total discounted at 5%</strong></td>
<td><strong>81.41</strong></td>
</tr>
<tr>
<td><strong>Linear extrapolation of the rate of Yag from 5 to 26 years of follow-up</strong></td>
<td></td>
</tr>
<tr>
<td>Laser Nd-Yag</td>
<td>22.48</td>
</tr>
<tr>
<td>Transient increase in IOP</td>
<td>0.71</td>
</tr>
<tr>
<td>Persistent increase in IOP</td>
<td>6.61</td>
</tr>
<tr>
<td>Persistent increase in IOP leading to blindness (indirect costs)</td>
<td>18.68</td>
</tr>
<tr>
<td>Glaucoma (direct costs)</td>
<td>8.86</td>
</tr>
<tr>
<td>Glaucoma leading to blindness (indirect costs)</td>
<td>25.03</td>
</tr>
<tr>
<td>Macular edema</td>
<td>0.30</td>
</tr>
<tr>
<td>Detachment of the retina</td>
<td>8.31</td>
</tr>
<tr>
<td>Decrease in visual acuity</td>
<td>9.19</td>
</tr>
<tr>
<td>Elschnig pearls</td>
<td>3.96</td>
</tr>
<tr>
<td><strong>Direct costs</strong></td>
<td><strong>60.46</strong></td>
</tr>
<tr>
<td><strong>Indirect costs</strong></td>
<td><strong>43.71</strong></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>104.17</strong></td>
</tr>
<tr>
<td><strong>Total discounted at 5%</strong></td>
<td><strong>84.78</strong></td>
</tr>
<tr>
<td><strong>Cost at 5 years</strong></td>
<td></td>
</tr>
<tr>
<td>Direct costs</td>
<td>30.79</td>
</tr>
<tr>
<td>Indirect costs</td>
<td>0.97</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>31.76</td>
</tr>
</tbody>
</table>

**Abbreviation:** Nd-Yag, neodymium-Yag; IOP, intraocular pressure.
additional cost adds up to between €33.9 and €35.9 million which has to be borne by Social Insurance.

**Discussion**

This economic study is principally based on the results obtained from a retrospective study whose principal objective was to estimate the rate of complications after cataract surgery with the insertion of three different IOL with square edges. The main complication was PCO and its treatment by laser Nd-Yag. This study showed that the lowest rate of capsulotomy was obtained with hydrophobic acrylic lenses and the highest rate with hydrophilic acrylic lenses. As the three lenses studied all had square edges, these results also illustrate the influence of material on the occurrence of Nd-Yag treatment independently of the geometric form of the edges of the lens.41–43

In a previous European study, we showed that the highest cost:efficacy ratio was observed with hydrophilic lenses and the lowest with hydrophobic lenses, in France, Germany, Spain and Italy.44 However, the lenses considered in this European study had very variable geometries. It is therefore difficult to know if the differences in cost estimated were due to material and/or the geometry of the lens.

The lenses studied here all had square edges, a geometry which is considered to be optimal, and the results demonstrate that material nevertheless plays an important role in the rate of capsulotomy and therefore on the cost of cataract surgery. The rate of PCO was highest with hydrophilic acrylic lenses, and the highest costs were also observed with the same lenses.

Generalization to other European countries should be performed cautiously since economic regulation might differ. However all countries having the following characteristics are likely to reproduce the reported results: (1) cost of IOL included in the DRG, (2) a fee-for-service payment for capsulotomy, (3) similar resource utilization and unit costs to treat capsulotomy adverse events.

The association between capsulotomy and retinal detachment was questioned by Neuhann et al45 in a paper published after this model was developed. While no association was reported, it is important to note that cost related to retinal detachment represented less than 8% of the SA60AT undiscounted total cost.

This study is limited by the following:

- It is based on a non-randomized retrospective study of efficacy and not on a prospective clinical trial. This fact may cause some potential bias but both designs, of course, have limitations that need to be remembered as the results are considered.
- Our work also does not involve standard criteria for assessing PCO. We are assuming surgeons evaluate clinically significant PCO in need of Nd-Yag intervention with reasonable consistency.
- Estimates of the cost of complications are based on the one hand on a review of literature reports of the rate of complications, and on the other on a declaration by clinicians of health care consumption associated with these complications. Considering the variability of data in the literature, we have mainly chosen studies in the literature involving large numbers of cases. Our estimates of the economic value of complications are based primarily on the literature or available national data. Thus, while every effort was made to maximize accuracy, there may be some imprecision in our estimates.

### Table 4

<table>
<thead>
<tr>
<th>Without linear adjustment of the rate of Yag at 5 and 6 years follow-up, then a constant rate</th>
<th>SA60AT</th>
<th>AR40E</th>
<th>XL-Stabi</th>
<th>Total difference*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current market share</td>
<td>204,045</td>
<td>63,598</td>
<td>74,198</td>
<td>341,842</td>
</tr>
<tr>
<td>With linear adjustment of the rate of Yag at 5 and 6 years follow-up, then a constant rate</td>
<td>18,459,158</td>
<td>12,053,962</td>
<td>21,365,979</td>
<td>51,879,100</td>
</tr>
<tr>
<td>Hypothesis 1: All interventions with SA60AT</td>
<td>30,925,117</td>
<td>64,790,569</td>
<td>12,911,469</td>
<td></td>
</tr>
<tr>
<td>Hypothesis 2: All interventions with AR40E</td>
<td>98,436,469</td>
<td>98,436,469</td>
<td>46,557,369</td>
<td></td>
</tr>
<tr>
<td>Hypothesis 3: All interventions with XL-Stabi</td>
<td>32,396,919</td>
<td>32,396,919</td>
<td>–20,953,983</td>
<td></td>
</tr>
</tbody>
</table>

*Difference: (Hypothesis i) – (Costs with current market share). A negative figure is associated with saving.
Also, we were not able to collect Nd-Yag complication data from patient charts and we had to rely on a model. In France, most of the ophthalmologists are not surgeons and the information is often shared by different practitioners, some of whom did not participate to this survey. More importantly, the incidence rate of Nd-Yag adverse events is fortunately low and the sample size of our survey would not have allowed getting precise estimates. This justifies the use of a model.

Following the literature review, we hypothesized that the Nd-Yag laser adverse events occurred within one year following the capsulotomy. We also hypothesized that, as reported in the literature, the listed (Table 1) adverse events were associated with the use of Nd-Yag laser, ie, they occurred on the top of what would have occurred in patients without Nd-Yag laser. This approach is acceptable when the incidence rate of the adverse event is much higher than the one observed in the general population. For example, the probability of having glaucoma after Nd-Yag laser (5%, Table 1) is x10 that measured in the general population (0.5%). Lastly, discounting gives more importance to early (Nd-Yag related events) events than late events (non Nd-Yag related events), minimizing the economic consequences of our hypotheses.

Cost of blindness was limited to indirect costs and did not include medical costs. Also, visual impairments due to macular edema and retinal detachment were not taken into account. Consequently, blindness-related costs were slightly underestimated both on a national health service and societal perspective.

Our results demonstrate that the costs of PCO are not limited to the cost of carrying out Nd-Yag laser but also include the cost of complications, some of which may be persistent. Indirect costs associated with the risk of blindness because of Yag complications represented about 21% of the total costs. Our study showed that it is possible to save money by using more effective strategies.

Disclosures and acknowledgments
This study was sponsored by Alcon Laboratories Ltd., Hemel Hempstead, England and conducted by Cemka-Eval, Bourg-la-Reine, France. Acrysof® is an Alcon trademark. Andrew Smith and Dr Gilles Berdeaux were Alcon employees. Dr Bouroua has participated in national health service trials sponsored by Alcon.

References


